Use of systemic immunomodulator xymedone in distructive pulmonary tuberculosis
Slabnov, I.D.; Vizel', A.A.; Cherepnev, G.V.; Firsov, O.V.; Sabirova, L.A.
Problemy Tuberkuleza 3: 28-32
2000
ISSN/ISBN: 0032-9533 PMID: 10900981 Document Number: 523166
The study was undertaken to examine 59 patients with destructive pulmonary tuberculosis who had T-cell dysfunction (loss of CD3+, CD4+, lymphocytes, slightly positive tuberculin test) and augmented IgA and IgG production. Oral Xymedone given in a dose 2.0 g daily for two 2 months in combination with antibacterial therapy abolished lymphopenia, restored CD4+ counts, CD4+/CD3+ ratio, upregulated IgG levels, but did not affect IgA levels. The Xymedone-treated patients developed fewer side effects due to basic antibacterial chemotherapy and showed more rapid culture conversion, resolution of pulmonary infiltration and closure of destructive cavities.